¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2030³â)
Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030
»óǰÄÚµå : 1560316
¸®¼­Ä¡»ç : Lucintel
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,800 £Ü 8,392,000
PDF (2 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,700 £Ü 9,694,000
PDF (5 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,850 £Ü 12,805,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ ±â¾÷ ³» ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½ºÀÇ µ¿Çâ ¹× ¿¹Ãø

¼¼°èÀÇ ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 11.2%·Î Àü¸ÁµÇ¸ç, 2030³â±îÁö ÃßÁ¤ 39¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ¾Ï ÀÌȯÀ² Áõ°¡¿Í ½ÉÇ÷°ü Áúȯ Ä¡·á¿¡ÀÇ ÀÀ¿ë Áõ°¡ÀÔ´Ï´Ù. ¼¼°è ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø, È­»ó Áø´Ü¼¾ÅÍ, Çмú ¹× ¿¬±¸ ±â°ü ½ÃÀå¿¡ ±âȸ°¡ ÀÖ¾î À¯¸Á½ÃµÇ°í ÀÖ½À´Ï´Ù.

LucintelÀº PET ÃßÀûÀÚ°¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÀÌ ½ÃÀå¿¡¼­ º´¿øÀº ±â¼úÀûÀ¸·Î ÷´Ü ½Ã½ºÅÛÀ» »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç º´¿ø ¼ö°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ÃÖ´ë ºÎ¹®À¸·Î °è¼Ó µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¸¸¼º Áúȯ Áõ°¡, ¹æ»ç¼º ÀǾàǰ ¹× ¹Ý·Áµ¿¹° ½ºÄ³³ÊÀÇ ÀÔ¼ö°¡ ¿ëÀÌÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº Áø´Ü ¹× Ä¡·á ±â¼úÀÇ Áøº¸¿¡ µû¶ó ±Þ¼ÓÈ÷ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. Áø´Ü°ú Ä¡·á¸¦ °áÇÕÇÑ Å×¶ó³ë½ºÆ½½º´Â ¸ÂÃãÇü ÀÇ·á, ƯÈ÷ Á¾¾çÇп¡¼­ Á߿伺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ½ÅÈï±¹ ½ÃÀå µ¿ÇâÀº ¹æ»ç¼ºÀǾàǰ °³¹ßÀÇ Çõ½Å, ±ÔÁ¦ÀÇ ÁøÀü, ´Ù¾çÇÑ º´Å¿¡ÀÇ ÀÀ¿ëÀÇ È®´ë¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ±â¼ú Áøº¸¿Í ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡·Î º¸´Ù ´ë»óÀ» Á¼È÷´Â È¿°úÀûÀÎ Ä¡·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖÀ½À» µÞ¹ÞħÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº ±â¼úÀÇ Áøº¸¿Í ÅõÀÚ Áõ°¡¿¡ ÀÇÇØ Å« º¯Çõ±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·á¿Í Áø´ÜÀÇ ÅëÇÕ, ¹æ»ç¼º ÇÙÁ¾ÀÇ ´Ù¾çÈ­, ¹æ»ç¼º Ç¥Áö »ýüºÐÀÚÀÇ °³¹ß, ¸ÂÃãÇü ÀÇ·á¿¡ÀÇ Á¢±Ù, ÅõÀÚ¿Í Çù·ÂÀÇ È°¼ºÈ­ µî ÁÖ¿ä µ¿ÇâÀÌ ÀÌ »óȲÀ» À籸ÃàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Á¤¹ÐÀÇ·á°¡ Á¡Á¡ ´õ Áß¿äÇØÁö°í º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃã Ä¡·áÀÇ ÀáÀç·ÂÀÌ ³ô¾ÆÁö°í ÀÖÀ½À» ¹Ý¿µÇϸç, ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ºÎ¹®ÀÇ ¿ªµ¿ÀûÀΠƯ¼ºÀ» µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½ ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº Á¤¹ÐÀǷḦ °­È­Çϱâ À§ÇÑ Áø´Ü ¹× Ä¡·á ¼ö´ÜÀÇ À¶ÇÕ¿¡ À־ÀÇ Å« Áøº¸¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü°ú Ç¥Àû Ä¡·á¸¦ À¶ÇÕÇÑ Å×¶ó³ë½ºÆ½½º´Â ±â¼ú Çõ½Å, ±ÔÁ¦ÀÇ ÁøÀü, ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±Þ¼ÓÈ÷ Áøº¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁøÀüÀº ƯÈ÷ ¾ÏÀ» ºñ·ÔÇÑ Áúº´ÀÇ Áø´Ü ¹× Ä¡·á ¹æ¹ýÀ» º¯È­½ÃÄÑ º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼ÇÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÇÏÀ̶óÀÌÆ®´Â ¹æ»ç¼º ÇÙÁ¾ÀÇ ÀÀ¿ë, Ä¡·á ¹× °øµ¿ ¿¬±¸ÀÇ ÁøÀüÀ̸ç, À̵éÀº ÃÑü·Î¼­ ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí, Å×¶ó³ë½ºÆ½ ÀÀ¿ëÀÇ ¹üÀ§¸¦ È®´ëÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº Ç¥Àû Ä¡·á ¹× Áø´ÜÀÇ ÇöÀúÇÑ Áøº¸¸¦ µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. FDA¿¡ ÀÇÇÑ ½Å±Ô¾àÀÇ ½ÂÀÎ, ½Å±Ô ¹æ»ç¼ºÇÙÁ¾ÀÇ ÃâÇö, ¹æ»ç¼ºÇ¥Áö »ýüºÐÀÚÀÇ Áøº¸, °³º°È­ÀÇ·áÀÇ ¼ºÀå, °øµ¿¿¬±¸¿Í ÅõÀÚ Áõ°¡ µî ÁÖ¿ä°³¹ßÀÌ ÀÌ ºÎ¹®ÀÇ Áøº¸¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â Ä¡·áÀÇ Á¤È®¼ºÀ» ³ôÀ̰í, Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í, Å×¶ó³ë½ºÆ½½º ½ÃÀå ÀüüÀÇ ¼ºÀå°ú ÁøÈ­¿¡ ±â¿©Çϸç, º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±æÀ» ¿­°í ÀÖ½À´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ Àü·«Àû ¼ºÀå ±âȸ

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº Áø´Ü ¹× Ä¡·á ±â¼úÀÇ Çõ½Å¿¡ ÀÇÇØ ±Þ¼ÓÈ÷ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. Å×¶ó³ë½ºÆ½½º´Â Ç¥Àû À̹Ì¡°ú Ä¡·á¸¦ ÅëÇÕÇϰí Á¤¹ÐÀÇ·á¿¡¼­ À¯¸ÁÇÑ ¼Ö·ç¼ÇÀ» ¼³¸íÇÕ´Ï´Ù. ½ÃÀåÀÌ ¼ºÀåÇÔ¿¡ µû¶ó ¸î °¡Áö ÁÖ¿ä ¿ëµµ¿¡ Àü·«Àû ¼ºÀå ±âȸ°¡ »ý±é´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ´Â Á¾¾çÇÐ, ¼øÈ¯±âÇÐ, ½Å°æÇаú °°Àº Å×¶ó³ë½ºÆ½½º°¡ ȯÀÚ Ä¡·á¸¦ Å©°Ô °­È­ÇÒ ¼ö ÀÖ´Â ºÎ¹®ÀÇ Áøº¸¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÀÌÇØ°ü°èÀÚ´Â ÀÌ·¯ÇÑ ¿ëµµ¸¦ Ȱ¿ëÇÔÀ¸·Î½á ±â¼ú Çõ½ÅÀ» ÃßÁøÇϰí, Ä¡·á ¼º°ú¸¦ Çâ»ó½Ã۰í, ½ÃÀå ¹üÀ§¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾Æ·¡¿¡¼­´Â ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå¿¡¼­ ´Ù¾çÇÑ ¿ëµµÀÇ ÁÖ¿ä ¼ºÀå ±âȸ¸¦ 5°³ °³·«ÀûÀ¸·Î ¼³¸íÇÕ´Ï´Ù.

¹æ»ç¼º ÀǾàǰ Å×¶ó³ë½ºÆ½ ½ÃÀå¿¡¼­ÀÇ Àü·«Àû ¼ºÀå ±âȸ´Â Á¾¾çÇÐ, ½Å°æÇÐ, ¼øÈ¯±âÇÐ, °¨¿°, ¸ÂÃãÇü ÀÇ·á µî ¿©·¯ °¡Áö ÁÖ¿ä ¿ëµµ¿¡ À̸£°í ÀÖ½À´Ï´Ù. °¢ ¿ëµµ´Â ¹æ»ç¼º ÀǾàǰ ±â¼úÀÇ Áøº¸¿Í ÀÓ»ó ÅëÇÕÀ» ÅëÇØ Çõ½Å°ú È®ÀåÀÇ µ¶Æ¯ÇÑ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÔÀ¸·Î½á ÀÌÇØ°ü°èÀÚ´Â Ä¡·áÀÇ Á¤È®¼ºÀ» ³ôÀ̰í, ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí, Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº ´Ù¾çÇÑ ±â¼úÀû, °æÁ¦Àû, ±ÔÁ¦Àû ¿äÀÎÀÇ ¿µÇâÀ» Å©°Ô ¹Þ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ¹æ»ç¼º ÀǾàǰ ±â¼úÀÇ Áøº¸, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÁöÁöÀûÀÎ ±ÔÁ¦ ȯ°æ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¹Ý´ë·Î ³ôÀº °³¹ß ºñ¿ë, ±ÔÁ¦ Àå¾Ö¹°, °ø±Þ¸Á ¹®Á¦ µîÀÇ ¹®Á¦´Â ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀΰú °úÁ¦¸¦ ÀÌÇØÇÏ´Â °ÍÀº Å×¶ó³ë½ºÆ½½º ºÎ¹®ÀÇ ±âȸ¸¦ Ȱ¿ëÇÏ·Á´Â ÀÌÇØ°ü°èÀÚ¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ¿äÀΰú ÇâÈÄ ¼ºÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °­Á¶ÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀ» °ßÀÎÇÏ´Â ¿äÀÎÀº ´ÙÀ½°ú °°½À´Ï´Ù.

1. ±â¼ú Áøº¸ : ¹æ»ç¼º ÀǾàǰ °³¹ßÀÇ ±â¼ú Áøº¸´Â Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¹æ»ç¼º ÇÙÁ¾ Á¦Á¶ °³¼±, ÷´Ü ¹æ»ç¼º Ç¥Áö ±â¼ú, À̹Ì¡ ±â¼ú °­È­ µîÀÇ ±â¼ú Çõ½ÅÀ» ÅëÇØ º¸´Ù Á¤¹ÐÇϰí È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á°¡ °¡´ÉÇÕ´Ï´Ù. º¸´Ù ¿ì¼öÇÑ Å¸°ÙÆÃ°ú ºÎÀÛ¿ë °¨¼Ò¸¦ ½ÇÇöÇÑ »õ·Î¿î ¹æ»ç¼º ÀǾàǰÀÇ °³Ã´Àº Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â °³Àο¡ ¸Â´Â Ä¡·á °èȹÀ» ¼¼¿ì±â ½¬¿öÁö°í, ´õ¿í ¸ÂÃãÇüÀ̰í È¿°úÀûÀÎ ÀÇ·á ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ±Ã±ØÀûÀ¸·Î ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

2. °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ : °³ÀÎÈ­µÈ ÀÇ·áÀÇ Á߿伺 Áõ°¡´Â ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù¹ýÀº À¯ÀüÀÚ, ºÐÀÚ, ¹ÙÀÌ¿À¸¶Ä¿ Á¤º¸¸¦ Ȱ¿ëÇÏ¿© °³º° ȯÀÚÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á¸¦ ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â µ¶Æ¯ÇÑ Áúº´ ¸¶Ä¿¸¦ ƯÀÌÀûÀ¸·Î Ç¥ÀûÈ­ÇÒ ¼ö ÀÖ´Â ¹æ»ç¼º ÀǾàǰÀÇ °³¹ßÀ» ÃËÁøÇÏ¿© º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃã Ä¡·á·Î À̾îÁý´Ï´Ù. ¸ÂÃãÇü ÀÇ·á ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó Çõ½ÅÀûÀÎ ¹æ»ç¼º ÀǾàǰ¿¡ ´ëÇÑ ¿ä±¸µµ Ä¿Áö°í ½ÃÀå È®´ë¿Í ¿¬±¸°³¹ßÀÇ Áö¼ÓÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

3. Áö¿ø ±ÔÁ¦ ȯ°æ : Áö¿ø ±ÔÁ¦ ȯ°æÀº ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. FDA¿Í EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº ¹æ»ç¼º ÀǾàǰÀÇ ½ÂÀÎ °úÁ¤À» °£¼ÒÈ­ÇÏ°í »õ·Î¿î ¾à¹°À» ½ÃÀå¿¡ ÅõÀÔÇϱâ À§ÇÑ ¸íÈ®ÇÑ °æ·Î¸¦ Á¦°øÇÕ´Ï´Ù. ½Å±Ô ¹æ»ç¼ºÁ¦¿¡ ´ëÇÑ ÃÖ±ÙÀÇ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÀÓ»ó½ÃÇè¿¡ °üÇÑ °¡À̵å¶óÀÎÀÇ È®¸³Àº ½ÃÀå ÁøÀÔÀ» ÃËÁøÇϰí ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº Çõ½ÅÀûÀÎ ¹æ»ç¼º ÀǾàǰÀÇ °³¹ß°ú »ó¾÷È­¸¦ °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¼ºÀå°ú Ä¡·á ¿É¼ÇÀÇ È®ÀåÀ» ÃËÁøÇÕ´Ï´Ù.

4. ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡: ¿¬±¸°³¹ß(R&D) ÅõÀÚ Áõ°¡´Â Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. Á¦¾à ȸ»ç, »ý¸í °øÇРȸ»ç ¹× ¿¬±¸ ±â°üÀº »õ·Î¿î ¹æ»ç¼º ÀǾàǰ ¹× ±â¼ú °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÅõÀÚ´Â »õ·Î¿î Ä¡·á, ÀÓ»ó½ÃÇè ¹× ±â¼ú Çõ½ÅÀÇ ¹ßÀüÀ» Áö¿øÇÕ´Ï´Ù. ¿¬±¸°³¹ß ÀÚ±Ý Áõ°¡´Â »õ·Î¿î Å×¶ó³ë½ºÆ½ ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϰí, Ä¡·á ¿É¼ÇÀ» ´Ã¸®°í, Áö¼ÓÀûÀÎ Çõ½ÅÀ» ÃËÁøÇϸç, ÀÌ¿ë °¡´ÉÇÑ ¾à¹° ÆÄÀÌÇÁ¶óÀÎÀ» È®´ëÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.

5. ÀÇ·áºÎ¹®¿¡¼­ÀÇ ÀÀ¿ë È®´ë : Á¾¾çÇÐ, ½Å°æÇÐ, ¼øÈ¯±âÇÐ, °¨¿°Áõ µî ´Ù¾çÇÑ ÀÇ·á ºÎ¹®¿¡¼­ ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½ºÀÇ ÀÀ¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Ä¡·á ¿µ¿ª¿¡¼­ Å×¶ó³ë½ºÆ½½º¸¦ Àû¿ëÇÒ ¼ö ÀÖ¾î Ä¡·á ¿É¼ÇÀÌ ³Ð¾îÁö°í ½ÃÀåÀÇ °¡´É¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. ¹æ»ç¼º ÀǾàǰÀÇ »õ·Î¿î ÀûÀÀÁõÀÌ È®ÀÎµÇ°í °³¹ßµÊ¿¡ µû¶ó ½ÃÀå¿¡¼­ ÀÌ·¯ÇÑ ±â¼ú ¼ö¿ä¿Í ÀÀ¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È®ÀåÀº ½ÃÀå ÀüüÀÇ Àü¸ÁÀ» ³ôÀÌ°í ¿©·¯ Ä¡·á ¿µ¿ª¿¡ °ÉÄ£ ¼ºÀå ±âȸ¸¦ ¼³¸íÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå °úÁ¦´Â ´ÙÀ½°ú °°½À´Ï´Ù.

1. ³ôÀº °³¹ß ¹× »ý»ê ºñ¿ë : ³ôÀº °³¹ß ¹× »ý»ê ºñ¿ëÀº ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå¿¡ Å« °úÁ¦ÀÔ´Ï´Ù. ¹æ»ç¼º ÀǾàǰÀÇ Á¦Á¶¿¡´Â ¹æ»ç¼º ÇÙÁ¾ÀÇ Á¦Á¶, ¹æ»ç¼º Ç¥Áö, ǰÁú °ü¸® µîÀÇ º¹ÀâÇÑ °øÁ¤ÀÌ Æ÷ÇԵDZ⠶§¹®¿¡ ´Ù¾×ÀÇ ÀÚ±Ý ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ºñ¿ëÀº »õ·Î¿î ¹æ»ç¼º ÀǾàǰÀÇ ÀÔ¼ö¸¦ Á¦ÇÑÇϰí Áß¼Ò±â¾÷ÀÌ ½ÃÀå¿¡ ÁøÀÔÇÒ ¶§ÀÇ À庮ÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë °úÁ¦¸¦ ÇØ°áÇÏ´Â °ÍÀº º¸´Ù ±¤¹üÀ§ÇÑ ½ÃÀå µµÀÔÀ» º¸ÀåÇϰí ÀÌ ºÎ¹®ÀÇ Áö¼Ó°¡´É¼ºÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

2. ±ÔÁ¦»óÀÇ Àå¾Ö¹° ¹× ½ÂÀÎ °úÁ¤ : ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô´Â ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ½ÂÀÎ °úÁ¤À» ±Øº¹ÇϱⰡ ¾î·Æ½À´Ï´Ù. ÀÓ»ó½ÃÇè, ¾ÈÀü¼º Æò°¡, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ¿ä±¸ »çÇ×Àº ½ÃÀå ÁøÀÔÀ» Áö¿¬½ÃŰ°í °³¹ß ±â°£À» ´Ã¸± ¼ö ÀÖ½À´Ï´Ù. Áö¿ª °£ ±ÔÁ¦ ±âÁØÀÇ Â÷ÀÌ´Â ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù. ±â¾÷Àº »õ·Î¿î ¾àÁ¦ÀÇ »ó½Ã¸¦ ¼º°ø½ÃŰ°í ¼¼°è ±âÁØ¿¡ÀÇ ÀûÇÕÀ» È®º¸Çϱâ À§Çؼ­ ÀÌ·¯ÇÑ ±ÔÁ¦»óÀÇ °úÁ¦¸¦ È¿°úÀûÀ¸·Î °ü¸®ÇØ¾ß ÇÕ´Ï´Ù.

3. °ø±Þ¸Á ¹× À¯Åë ¹®Á¦ : °ø±Þ¸Á ¹× À¯Åë ¹®Á¦´Â ¹æ»ç¼º ÀǾàǰÀÇ °¡¿ë¼º°ú ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¹æ»ç¼º ÀǾàǰÀÇ Á¦Á¶¿Í À¯ÅëÀº Ưº°ÇÑ Ãë±Þ°ú º¸°ü Á¶°ÇÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ º¹ÀâÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ¹æ»ç¼º ÇÙÁ¾ Á¦Á¶ Áö¿¬°ú ¹°·ù ¹®Á¦ µî °ø±Þ¸Á¿¡ È¥¶õÀÌ »ý±â¸é ÀÇ·á Á¾»çÀÚ¿¡°Ô Àû½Ã¿¡ Á¦Ç° °ø±Þ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °ø±Þ¸Á ¹®Á¦¸¦ ÇØ°áÇÏ´Â °ÍÀº Á¦Ç°ÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» º¸ÀåÇÏ°í ½ÃÀå ¼ö¿ä¸¦ ÃæÁ·½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº ±â¼ú °³Ã´, ¸ñÇ¥ Ä¡·á ¼ö¿ä Áõ°¡, À¯¸®ÇÑ ½ÃÀå Á¤Ã¥, ¿¬±¸°³¹ß ÀÚ±Ý Áõ°¡, ÀÇ·á ºÐ¾ß¿¡¼­ º¸´Ù ±¤¹üÀ§ÇÑ ¿ëµµ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, ±ÔÁ¦ÀÇ ¾î·Á¿ò, °ø±Þ¸ÁÀÇ ¾î·Á¿ò µî °í·ÁÇØ¾ß ÇÒ Å« À庮µµ ÀÖ½À´Ï´Ù. ¾î·µç ½ÃÀåÀÌ ´õ¿í ¹ßÀüÇÏ°í ¹ø¿µÇϱâ À§Çؼ­´Â ÀÌ¿ë °¡´ÉÇÑ Àü¸ÁÀ» Ȱ¿ëÇϰí Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¿ªµ¿ÀûÀÎ »óȲ¿¡ Á¸ÀçÇÏ´Â °úÁ¦¸¦ ÇØ°áÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â °ü°èÀÚÀÇ °ßÇØÇÏ¿¡ ¹®Á¦ Áß ÀϺθ¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½ºÀÇ ºÎ¹®º° ¿¹Ãø

º» Á¶»ç¿¡¼­´Â ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½ºÀÇ Á¦Ç° À¯Çüº°, °ø±Þ¿øº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ¼¼°è ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù.

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ±¹°¡º° Àü¸Á

¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº Áø´Ü°ú Ä¡·á Á¢±ÙÀÇ ÅëÇÕÀÌ ¾Ï Ä¡·á¿Í ¸ÂÃãÇü ÀǷḦ º¯È­½ÃŰ´Â °¡¿îµ¥ ÇöÀúÇÑ Áøº¸¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¹Ì±¹, Áß±¹, µ¶ÀÏ, Àεµ, ÀϺ»À» Æ÷ÇÔÇÑ ÁÖ¿ä Áö¿ªÀÇ ÃÖ±Ù µ¿ÇâÀº Ç¥Àû Ä¡·á, Çõ½ÅÀûÀÎ ¹æ»ç¼º ÀǾàǰ ¹× ÀÓ»ó ÀÀ¿ëÀÇ °­È­¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÏ´Â Á¤¹ÐÀÇ·áÀÇ Á߿伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ½À» µÞ¹ÞħÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ¿ä ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº ´ÙÀ½°ú °°½À´Ï´Ù.

ÀÚÁÖ ¹¯´Â Áú¹®

Q1. ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå ±Ô¸ð´Â?

´äº¯ : ¼¼°èÀÇ ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº 2030³â±îÁö ÃßÁ¤ 39¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q2. ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¼ºÀå ¿¹ÃøÀº?

´äº¯ : ¼¼°èÀÇ ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö 11.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q3. ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

´äº¯ : ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ¾Ï ÀÌȯÀ² Áõ°¡¿Í ½ÉÇ÷°ü Àå¾ÖÀÇ Ä¡·á¿¡¼­ ¿ëµµ Áõ°¡ÀÔ´Ï´Ù.

Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

´äº¯ : ¼¼°è ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø, ¿µ»ó Áø´Ü¼¾ÅÍ, Çмú ¹× ¿¬±¸ ±â°ü ½ÃÀå¿¡¼­ÀÇ ±âȸ¿¡ ÀÇÇØ À¯¸Á½ÃµÇ°í ÀÖ½À´Ï´Ù.

Q5. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

´äº¯ : ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

Q6. ÇâÈÄ °¡Àå Å« ½ÃÀå ºÎ¹®Àº?

´äº¯ : LucintelÀº PET Æ®·¹À̼­°¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Q7. ½ÃÀå¿¡¼­ ÇâÈÄ 5³â°£ ÃÖ´ë°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº?

´äº¯ : ºÏ¹Ì´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¹æ»ç¼º ÀǾàǰ ¹× PET ½ºÄ³³ÊÀÇ ÀÔ¼ö°¡ ¿ëÀÌÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Q8. º¸°í¼­ÀÇ Ä¿½ºÅ͸¶ÀÌÁî´Â °¡´ÉÇѰ¡?

´äº¯ : ³×, LucintelÀº Ãß°¡ ºñ¿ë ¾øÀÌ 10% »ç¿ëÀÚ Á¤ÀǸ¦ ¼³¸íÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¹æ»ç¼ºÀǾàǰ Å×¶ó³ë½ºÆ½½º ½ÃÀå : ½ÃÀå ¿ªÇÐ

Á¦3Àå ½ÃÀå µ¿Çâ ¹× ¿¹Ãø ºÐ¼®(2018-2030³â)

Á¦4Àå ½ÃÀå µ¿Çâ ¹× ¿¹Ãø ºÐ¼® : Áö¿ªº°(2018-2030³â)

Á¦5Àå °æÀï ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ ¹× Àü·« ºÐ¼®

Á¦7Àå ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ ÇÁ·ÎÆÄÀÏ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Radiopharmaceutical Theranostics Trends and Forecast

The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Within this market, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.

North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Emerging Trends in the Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is evolving rapidly with advancements in both diagnostic and therapeutic technologies. Theranostics, which combines diagnostics and therapy, is becoming increasingly significant in personalized medicine, particularly in oncology. Emerging trends in this market reflect innovations in radiopharmaceutical development, regulatory advancements, and growing applications across various medical conditions. These trends underscore the ongoing shift towards more targeted and effective treatments, enhanced by technological progress and increasing investment in research and development.

The radiopharmaceutical theranostics market is undergoing significant transformation driven by advancements in technology and increased investment. Key trends such as the integration of targeted therapies and diagnostics, diversification of radionuclides, development of radiolabeled biomolecules, personalized medicine approaches, and heightened investment and collaboration are reshaping the landscape. These trends reflect the growing emphasis on precision medicine and the potential for more effective and personalized treatments, highlighting the dynamic nature of the radiopharmaceutical theranostics sector.

Recent Developments in the Radiopharmaceutical Theranostics Market

Recent developments in the radiopharmaceutical theranostics market reflect significant strides in combining diagnostic and therapeutic modalities to enhance precision medicine. Theranostics, which merges imaging and targeted therapy, is advancing rapidly due to technological innovations, regulatory progress, and increased focus on personalized treatment approaches. These developments are transforming how diseases, particularly cancer, are diagnosed and treated, leading to more effective and tailored healthcare solutions. Key advancements in this market highlight progress in radionuclide applications, therapeutic agents, and collaborative efforts, which collectively improve patient outcomes and expand the scope of theranostic applications.

Recent developments in the radiopharmaceutical theranostics market highlight significant advancements in targeted therapies and diagnostics. Key developments, including FDA approvals of new agents, emergence of novel radionuclides, advancements in radiolabeled biomolecules, the growth of personalized medicine, and increased collaboration and investment, are driving progress in the field. These advancements are enhancing treatment precision, expanding therapeutic options, and contributing to the overall growth and evolution of the theranostics market, paving the way for more effective and individualized healthcare solutions.

Strategic Growth Opportunities for Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is evolving rapidly, driven by innovations in diagnostic and therapeutic technologies. Theranostics integrates targeted imaging and treatment, offering promising solutions in precision medicine. As the market grows, several key applications present strategic growth opportunities. These opportunities reflect advancements in oncology, cardiology, neurology, and other areas where theranostics can significantly enhance patient care. By leveraging these applications, stakeholders can drive innovation, improve treatment outcomes, and expand market reach. The following outlines five key growth opportunities across various applications in the radiopharmaceutical theranostics market.

Strategic growth opportunities in the radiopharmaceutical theranostics market span several key applications, including oncology, neurology, cardiology, infectious diseases, and personalized medicine. Each application offers unique potential for innovation and expansion, driven by advancements in radiopharmaceutical technologies and their integration into clinical practice. By capitalizing on these opportunities, stakeholders can enhance treatment precision, improve patient outcomes, and drive the continued growth of the theranostics market.

Radiopharmaceutical Theranostics Market Driver and Challenges

The radiopharmaceutical theranostics market is significantly influenced by various technological, economic, and regulatory factors. Major drivers of growth include advancements in radiopharmaceutical technologies, increased demand for personalized medicine, and supportive regulatory environments. Conversely, challenges such as high development costs, regulatory hurdles, and supply chain issues impact market dynamics. Understanding these drivers and challenges is crucial for stakeholders seeking to navigate and capitalize on opportunities within the theranostics sector. This analysis highlights the key factors shaping the market and their implications for future growth.

The factors responsible for driving the radiopharmaceutical theranostics market include:

1. Technological Advancements: Technological advancements in radiopharmaceutical development are a primary driver of the theranostics market. Innovations such as improved radionuclide production, advanced radiolabeling techniques, and enhanced imaging technologies enable more precise and effective diagnostics and therapies. The development of novel radiopharmaceutical agents with better targeting and reduced side effects is expanding treatment options and increasing market demand. These advancements facilitate the creation of personalized treatment plans, ultimately driving market growth by offering more tailored and effective healthcare solutions.

2. Growing Demand for Personalized Medicine: The increasing emphasis on personalized medicine is significantly impacting the radiopharmaceutical theranostics market. Personalized medicine approaches leverage genetic, molecular, and biomarker information to tailor treatments to individual patient profiles. This trend drives the development of theranostic agents that can specifically target unique disease markers, leading to more effective and individualized treatments. As the demand for personalized healthcare solutions grows, so does the need for innovative radiopharmaceuticals, boosting market expansion and encouraging ongoing research and development.

3. Supportive Regulatory Environment: A supportive regulatory environment is a key driver for the growth of the radiopharmaceutical theranostics market. Regulatory agencies, such as the FDA and EMA, have streamlined approval processes for radiopharmaceuticals, providing clearer pathways for bringing new agents to market. Recent regulatory approvals for novel theranostic agents and the establishment of guidelines for clinical trials have facilitated market entry and encouraged investment. This regulatory support helps accelerate the development and commercialization of innovative radiopharmaceuticals, fostering market growth and expanding treatment options.

4. Increased Investment in Research and Development: The rising investment in research and development (R&D) is a significant driver of growth in the theranostics market. Pharmaceutical companies, biotech firms, and research institutions are investing heavily in the development of new radiopharmaceutical agents and technologies. This investment supports the advancement of novel therapies, clinical trials, and technological innovations. Increased R&D funding accelerates the introduction of new theranostic solutions, enhances treatment options, and drives market growth by fostering continuous innovation and expanding the pipeline of available agents.

5. Expanding Applications Across Medical Fields: The expansion of radiopharmaceutical theranostics applications across various medical fields, including oncology, neurology, cardiology, and infectious diseases, is driving market growth. The ability to apply theranostics in diverse therapeutic areas broadens the scope of treatment options and increases market potential. As new indications for radiopharmaceuticals are identified and developed, the market sees increased demand and application of these technologies. This expansion enhances the overall market landscape and provides opportunities for growth across multiple therapeutic domains.

Challenges in the radiopharmaceutical theranostics market are:

1. High Development and Production Costs: High development and production costs pose a significant challenge to the radiopharmaceutical theranostics market. The complex processes involved in producing radiopharmaceuticals, including radionuclide production, radiolabeling, and quality control, require substantial financial investment. These high costs can limit the accessibility of new theranostic agents and create barriers for smaller companies entering the market. Addressing these cost challenges is essential for ensuring broader market adoption and maintaining the sustainability of the sector.

2. Regulatory Hurdles and Approval Processes: Navigating regulatory hurdles and approval processes can be challenging for companies in the radiopharmaceutical theranostics market. The stringent requirements for clinical trials, safety assessments, and regulatory approvals can delay market entry and increase development timelines. Differences in regulatory standards across regions can further complicate the approval process. Companies must effectively manage these regulatory challenges to successfully bring new theranostic agents to market and ensure compliance with global standards.

3. Supply Chain and Distribution Issues: Supply chain and distribution issues can impact the availability and market growth of radiopharmaceuticals. The production and distribution of radiopharmaceuticals are often complex due to the need for specialized handling and storage conditions. Any disruptions in the supply chain, such as delays in radionuclide production or logistical challenges, can affect the timely delivery of products to healthcare providers. Addressing these supply chain challenges is crucial for ensuring consistent product availability and meeting market demand.

The radiopharmaceutical theranostics market is driven by multiple factors such as technological development, increasing demand for targeted therapies, favorable market policies, increased funding for R & D, and more wide-ranging uses within medicine. However, there are significant barriers such as high costs of development, regulatory difficulties, and supply chain difficulties that must be taken into account. In any case, some of these issues must be accommodated in order for the market to further develop and prosper under the view of the parties involved that aim to capitalize on the available prospects and counter the challenges that exist in the dynamic landscape of the theranostics market.

List of Radiopharmaceutical Theranostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiopharmaceutical theranostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiopharmaceutical theranostics companies profiled in this report include-

Radiopharmaceutical Theranostics by Segment

The study includes a forecast for the global radiopharmaceutical theranostics by product type, source, indication, end use, and region.

Radiopharmaceutical Theranostics Market by Product Type [Analysis by Value from 2018 to 2030]:

Radiopharmaceutical Theranostics Market by Source [Analysis by Value from 2018 to 2030]:

Radiopharmaceutical Theranostics Market by Indication [Analysis by Value from 2018 to 2030]:

Radiopharmaceutical Theranostics Market by End Use [Analysis by Value from 2018 to 2030]:

Radiopharmaceutical Theranostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

Country Wise Outlook for the Radiopharmaceutical Theranostics Market

The radiopharmaceutical theranostics market is witnessing significant advancements as the integration of diagnostics and therapeutic approaches transforms cancer treatment and personalized medicine. Recent developments in this market across key regions-including the United States, China, Germany, India, and Japan-reflect progress in targeted therapies, innovative radiopharmaceuticals, and enhanced clinical applications. These developments underscore the growing importance of precision medicine in improving patient outcomes and optimizing treatment efficacy. Here's a look at recent developments in these key markets:

Features of the Global Radiopharmaceutical Theranostics Market

Market Size Estimates: Radiopharmaceutical theranostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiopharmaceutical theranostics market size by various segments, such as by product type, source, indication, end use, and region in terms of value ($B).

Regional Analysis: Radiopharmaceutical theranostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, sources, indications, end uses, and regions for the radiopharmaceutical theranostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiopharmaceutical theranostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the radiopharmaceutical theranostics market size?

Answer: The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030.

Q.2 What is the growth forecast for radiopharmaceutical theranostics market?

Answer: The global radiopharmaceutical theranostics market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the radiopharmaceutical theranostics market?

Answer: The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Q4. What are the major segments for radiopharmaceutical theranostics market?

Answer: The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets.

Q5. Who are the key radiopharmaceutical theranostics market companies?

Answer: Some of the key radiopharmaceutical theranostics companies are as follows:

Q6. Which radiopharmaceutical theranostics market segment will be the largest in future?

Answer: Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Q7. In radiopharmaceutical theranostics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Global Radiopharmaceutical Theranostics Market : Market Dynamics

3. Market Trends and Forecast Analysis from 2018 to 2030

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

5. Competitor Analysis

6. Growth Opportunities and Strategic Analysis

7. Company Profiles of Leading Players

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â